Sano Y, Maruyama S, Aoe M, Date H, Shimizu N
Second Department of Surgery, Okayama University Medical School, Japan.
Surg Today. 1996;26(12):999-1005. doi: 10.1007/BF00309961.
Orthotopic left lung grafts from Brown Norway (BN) donors were transplanted to Lewis (LEW) rat recipients which had been treated with a single dose of FK506 10mg/kg body weight intramuscularly on postoperative day 3. Although the lungs were rejected with a median survival time of 7 days, with a range of 6-8 days in the untreated controls, maximum survival was prolonged to 60 days. The major adverse effects of this therapy were reduction of feeding, loss of body weight, and diarrhea. One of the 7 rats died on the 21st postoperative day due to anorexia. The effects of this therapy were investigated by histopathological examination and flow cytometric analysis using monoclonal antibodies against rat lymphocytes: OX-39 (anti-interleukin 2 receptor (IL-2R)) and OX-6 (anti-class II MHC). Histopathologically, the lung allografts showed mild perivascular and peribronchiolar cuffs of mononuclear cells, while marked reduction of the thymic medulla with FK506 treatment was also observed. Flow cytometric analysis of the transplanted lung showed no significant changes. Regarding the thymus, the percentages of positive cells labeled with OX-39 and OX-6 were significantly suppressed after this treatment. In the spleen, the number of OX-6-positive cells significantly decreased. The results using this therapy thus suggest that the suppression of IL-2R and MHC class II expression was systemically maintained for a long time.
将来自棕色挪威(BN)供体的原位左肺移植到刘易斯(LEW)大鼠受体中,这些受体在术后第3天接受了单剂量10mg/kg体重的FK506肌肉注射治疗。尽管在未治疗的对照组中,肺移植在中位生存时间7天(范围为6 - 8天)时被排斥,但该治疗使最大生存时间延长至60天。这种治疗的主要不良反应是进食减少、体重减轻和腹泻。7只大鼠中有1只在术后第21天因厌食死亡。通过组织病理学检查和使用抗大鼠淋巴细胞单克隆抗体的流式细胞术分析来研究这种治疗的效果:OX - 39(抗白细胞介素2受体(IL - 2R))和OX - 6(抗II类主要组织相容性复合体(MHC))。组织病理学上,肺同种异体移植显示轻度血管周围和支气管周围单核细胞套袖状浸润,同时也观察到FK506治疗导致胸腺髓质明显减少。对移植肺的流式细胞术分析未显示明显变化。关于胸腺,该治疗后用OX - 39和OX - 6标记的阳性细胞百分比显著受到抑制。在脾脏中,OX - 6阳性细胞数量显著减少。因此,使用这种治疗的结果表明,IL - 2R和II类MHC表达的抑制在全身被长期维持。